Similar articles

• Lymphoid resistant responses to in vitro immunosuppression in renal transplant recipients: increased incidence of refractory episodes.

  Bowes LG, Dumble LJ, Clunie GJ, Francis DM, Macdonald IM, Kincaid-Smith P. Bowes LG, et al. Transplant Proc. 1988 Feb;20(1):20-2. Transplant Proc. 1988. PMID: 2964112 No abstract available.
• OKT3 treatment of steroid- and/or anti-thymocyte globulin-resistant renal allograft rejection occurring on triple baseline immunosuppression including cyclosporine A.

  Widmer U, Frei D, Keusch G, Burger HR, Largiader F, Binswanger U. Widmer U, et al. Transplant Proc. 1988 Oct;20(5 Suppl 6):90-5. Transplant Proc. 1988. PMID: 3140454 No abstract available.
• Increased risk of rejection in renal transplant recipients with in vitro cyclosporin-resistant lymphoid responses.

  Bowes LG, Dumble LJ, Clunie GJ, Francis DM, Macdonald IM, Kincaid-Smith P. Bowes LG, et al. Transplant Proc. 1989 Feb;21(1 Pt 2):1470-1. Transplant Proc. 1989. PMID: 2523587 No abstract available.
• Control of rejection of transplanted organs.

  Keown PA, Stiller CR. Keown PA, et al. Adv Intern Med. 1986;31:17-46. Adv Intern Med. 1986. PMID: 3511616 Review. No abstract available.
• Relevant targets for therapy with monoclonal antibodies in allograft transplantation.

  Soulillou JP. Soulillou JP. Kidney Int. 1994 Aug;46(2):540-53. doi: 10.1038/ki.1994.306. Kidney Int. 1994. PMID: 7967369 Review. No abstract available.